• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Global Biosimilars Market - Products, Applications and Regulations
 

Global Biosimilars Market - Products, Applications and Regulations

on

  • 1,192 views

Several of the leading 25 manufacturers of biosimilars have been entrenched in the market, and have the experience of marketing products for the last 5-10 years. On the other hand, several ...

Several of the leading 25 manufacturers of biosimilars have been entrenched in the market, and have the experience of marketing products for the last 5-10 years. On the other hand, several companies’ position is expected to be challenged over the next ten years, since the rapid growth forecast for the biosimilars market has attracted several new companies to enter this lucrative arena. Current leaders, in order to maintain market share, need to introduce new biosimilars over the next few years with a specific focus on the products in demand. Licensing deals are expected to expand the pipelines of established players, as well as new market entrants.
The global biosimilar market, estimated at US$2 billion in 2012 and expected to touch US$2.7 billion in 2013, is further projected to reach US$19.4 billion by 2018, exhibiting a CAGR of 36.6% over 2009-2018. This growth can be attributed to some of the top-selling biologics coming off-patent over the coming few years and biosimilar manufacturers are bound to make a beeline towards this lucrative opportunity.This report reviews, analyzes and projects the biosimilars market for global and regional markets including the United States, Europe, Asia-Pacific and Rest of World. The market numbers illustrated in this report only represent the market exclusively for the product segments and application areas enunciated above. The regional markets further analyzed for 8 more independent countries across Europe – France, Germany, Italy, Spain, the United Kingdom and Rest of Europe; Asia-Pacific – China, India, South Korea and Rest of Asia-Pacific.
The market for application areas of biosimilars analyzed in this study includes Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Others. The report also encompasses the market analysis for product segments – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Others.
This 354 page global market report includes 149 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of the market. The statistical tables represent the data for the global market by geographic region, application area and product segment.The report covers the brief business profiles of 43 key global players and 54 major players across the United States – 13; Europe – 18; Asia-Pacific – 19 and Rest of World – 4. The report also provides the listing of the companies engaged in research and development, manufacturing, processing, supplies and distribution of biosimilars. Also enlisting the academic institutions and industry associations engaged in biosimilars, the global list covers the addresses, contact numbers and the website addresses of 168 companies.

Statistics

Views

Total Views
1,192
Views on SlideShare
1,163
Embed Views
29

Actions

Likes
0
Downloads
44
Comments
0

2 Embeds 29

https://twitter.com 28
https://abs.twimg.com 1

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Global Biosimilars Market - Products, Applications and Regulations Global Biosimilars Market - Products, Applications and Regulations Document Transcript

    • Nov 2012 GLOBAL BIOSIMILARS MARKET PRODUCTS, APPLICATIONS AND REGULATIONS TABLE 0F CONTENTSSeveral of the leading 25 manufacturers of biosimilars have been entrenched in the market, and have theexperience of marketing products for the last 5-10 years. On the other hand, several companies’ position isexpected to be challenged over the next ten years, since the rapid growth forecast for the biosimilarsmarket has attracted several new companies to enter this lucrative arena. Current leaders, in order tomaintain market share, need to introduce new biosimilars over the next few years with a specific focus onthe products in demand. Licensing deals are expected to expand the pipelines of established players, aswell as new market entrants.The global biosimilar market, estimated at US$2 billion in 2012 and expected to touch US$2.7 billion in2013, is further projected to reach US$19.4 billion by 2018, exhibiting a CAGR of 36.6% over 2009-2018.This growth can be attributed to some of the top-selling biologics coming off-patent over the coming fewyears and biosimilar manufacturers are bound to make a beeline towards this lucrative opportunity. Thisreport reviews, analyzes and projects the biosimilars market for global and regional markets including theUnited States, Europe, Asia-Pacific and Rest of World. The market numbers illustrated in this report onlyrepresent the market exclusively for the product segments and application areas enunciated above. Theregional markets further analyzed for 8 more independent countries across Europe – France, Germany,Italy, Spain, the United Kingdom and Rest of Europe; Asia-Pacific – China, India, South Korea and Rest ofAsia-Pacific.The market for application areas of biosimilars analyzed in this study includes Blood Disorders, ChronicDiseases, Growth Hormone Deficiency, Oncology and Others. The report also encompasses the marketanalysis for product segments – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin,G-CSF, Interferons and Others.This 354 page global market report includes 149 charts (includes a data table and graphical representationfor each chart), supported with meaningful and easy to understand graphical presentation, of the market.The statistical tables represent the data for the global market by geographic region, application area andproduct segment. The report covers the brief business profiles of 43 key global players and 54 majorplayers across the United States – 13; Europe – 18; Asia-Pacific – 19 and Rest of World – 4. The report alsoprovides the listing of the companies engaged in research and development, manufacturing, processing,supplies and distribution of biosimilars. Also enlisting the academic institutions and industry associationsengaged in biosimilars, the global list covers the addresses, contact numbers and the website addresses of168 companies. © Industry Experts, All Rights Reserved -i-
    • Nov 2012 GLOBAL BIOSIMILARS MARKET PRODUCTS, APPLICATIONS AND REGULATIONS TABLE 0F CONTENTSPART A: GLOBAL MARKET PERSPECTIVE1. INTRODUCTION1.1 mAbs - All The Rage In Biosimilars’ New Wave1.2 The Buildup to the Biosimilar Industry1.3 Current Players: A Sneak Preview1.3.1 Celltrion1.3.2 Gedeon Richter1.3.3 Biocon1.4 The Big Pharma Industry: Not One to be Left Out1.4.1 Baxter-Momenta1.4.2 Merck Serono-Dr. Reddy’s Laboratories1.4.3 Daiichi Sankyo-Coherus Biosciences1.4.4 Amgen-Watson1.4.5 Samsung Biologics-Biogen Idec1.5 On the Flip Side1.6 The Winner Takes It All1.7 Product Outline1.7.1 What are Biosimilars?1.7.2 The Process of Approval1.7.3 Backdrop1.7.4 The Biologics Price Competition and Innovation Act1.7.4.1 Data Exclusivity1.7.5 Biosimilars by Product Type1.7.5.1 Monoclonal Antibodies1.7.5.1.1 Production Process1.7.5.2 Erythropoietin1.7.5.2.1 Functions of EPO1.7.5.2.2 Mechanism of Action1.7.5.2.3 Synthesis and Regulation1.7.5.2.4 Uses in Medicine1.7.5.3 Human Growth Hormone1.7.5.3.1 Recombinant Human Growth Hormone1.7.5.3.2 Managing Growth Disorders Using Recombinant Human Growth Hormone Biosimilars1.7.5.4 Insulin1.7.5.4.1 Biosimilar Insulin1.7.5.4.2 The Complexity in Producing Biosimilar Insulin1.7.5.4.3 Biosimilars and the Regulatory Environment Surrounding Them1.7.5.4.4 The Market for Insulin Biosimilars1.7.5.5 Granulocyte Colony-Stimulating Factor1.7.5.5.1 Biological Function1.7.5.5.2 Genetics1.7.5.5.3 Use in Therapeutics1.7.5.6 Interferons1.7.5.6.1 Interferon Categorization1.7.5.6.2 Functions of Interferons1.7.5.6.3 Interferon Alfa1.7.5.6.4 Interferon Beta-1a © Industry Experts, All Rights Reserved -ii-
    • Nov 2012 GLOBAL BIOSIMILARS MARKET PRODUCTS, APPLICATIONS AND REGULATIONS TABLE 0F CONTENTS1.7.5.6.5 Interferon Gamma1.7.5.7 Other Biosimilars2. BIOSIMILAR APPLICATIONS – A SNAPSHOT2.1 Blood Disorders2.2 Chronic and Autoimmune Diseases2.3 Growth Hormone Deficiency2.3.1 Growth Hormone Deficiency in Children2.4 Oncology2.4.1 Biosimilars in Oncology and Hematology2.4.2 Biosimilar G-CSF3. REGULATORY LANDSCAPE3.1 The United States Food and Drug Administration3.2 European Medicines Agency3.3 Other Developments on the Biosimilar Front3.3.1 The World Health Organization3.3.2 Canada3.3.3 Japan3.3.4 Latin America3.3.4.1 Argentina3.3.4.2 Brazil3.3.4.3 Mexico3.3.5 India4. KEY MARKET TRENDSBiosimilars Growth to be Driven by Emerging Markets over the Next DecadeAsia Poised to Manufacturing Hub for BiosimilarsBiosimilars: Present Perspectives and Future ImplicationsKey Considerations for Biosimilars Development and Commercialization in the USThe FDA GuidelinesAn Assessment of the Current and Future Trends Of Biosimilars in the United States and IndiaBiosimilars: Some Quick FactsThe United States Market for BiosimilarsThe Indian Market for BiosimilarsBiosimilars could Drive-Down the Cost of Cancer TreatmentFDA Draft Guidance Triggers Evaluation of IP ProtectionBiosimilar Therapeutics Showing ‘Similarity’Key Issues in Biosimilars CommercializationBiosimilars in the US: Regulation, Strategies, and ImpactOncologists Urged to Consider Biosimilars as Cost-Effective Treatment OptionsBiosimilars Development: Opportunities and ChallengesKey Biosimilar Developments During 2011Biosimilars Business Blooming in IndiaProspectsIndian Initiatives…Roadblocks RemainOpportunities for Biosimilars in Emerging Markets5. KEY GLOBAL PLAYERS © Industry Experts, All Rights Reserved -iii-
    • Nov 2012 GLOBAL BIOSIMILARS MARKET PRODUCTS, APPLICATIONS AND REGULATIONS TABLE 0F CONTENTS6. KEY BUSINESS TRENDSProCognia to expand biosimilar collaboration with UniTargeting ResearchOncobiologics, Boston Oncology to Commercialize Biosimilar Therapies in MENA regionInnovent Biologics Engages Pharmatech Associates for Designing Biosimilars Facility in ChinaSandoz Initiates Phase-III Trial for Epoetin AlfaAET BioTech, BioXpress Therapeutics Sign Deal for Cancer mAbReliance Life Sciences Starts Biosimilar Infliximab Trial in IndiaFujifilm Kyowa Kirin Biologics to Develop Bevacizumab BiosimilarRoche’s Rituxan Biosimilar Copies in Market By 2015Asian Biotech Companies to Pioneer Biosimilars for Renal FailureDr Reddy’s Negotiating for Europe Reditux debutFDA approves Teva Cancer Treatment BiosimilarFDA Approves Teva’s Tbo-filgrastim VersioniBio and GE Healthcare Announce Global AllianceSynthon Strikes Deal for Developing Herceptin BiosimilarStakeholder Groups Urging FDA to Exempt Plasma Protein Therapy from Biosimilar PathwayRanbaxy to Commercialize Three Biosimilars by 2015Korean FDA Approves Celltrion’s First Monoclonal AntibodyBiocon Announces Positive Results for Biosimilar Insulin Glargine Phase I TrialDr Reddys to Collaborate with Merck Serono on BiosimilarsIndia Announces New Regulations for BiosimilarsAbbott Challenging Provision in Federal Biosimilar LawAmgen Endorses EMA Guidance on Biosimilar mAbFinox Biotech Completes Phase III Trial of Biosimilar r-FSHCourt Rules against Merck in Nasonex Patent Infringement CasePlantForm’s Biosimilar Trastuzumab Equivalent to Brand Drug In VivoDaiichi Sankyo, Coherus BioSciences in Biosimilar DealAmgen, PRA in Biosimilars DealPfizer Starts Biosimilar Rituximab Phase I/II trialDaiichi Sankyo, Coherus Biosciences Collaborating to Commercialize BiosimilarsEMA Reviewing Biosimilar Version of InfliximabSamsung to Launch Cheaper Biosimilars by 2015Biocon Commences Advanced Research Centre in BangaloreAmgen Seeking Clinical Trial Clarification on BiosimilarsFujifilm, Kyowa in Joint Venture for HumiraDr Reddy’s Betting High on BiosimilarsGE Healthcare Acquires Xcellerex to Expand Biologicals OfferingCelerion, Ricerca in Biosimilar AllianceBiocon and Pfizer Conclude Commercialization AgreementSamsung Biologics and Biogen Idec from Biosimilars Joint VentureSandoz Initiates Phase III Trials for Filgrastim and PegfilgrastimHospira begins US Phase III Trial for Biosimilar EPOMochida, Fuji Pharma File Biosimilar G-CSF in JapanTransgene Moves rh-EPO Technology to German TSS ExportMomenta, Baxter in Biosimilar AllianceAmgen Issued New US Patent on EnbrelBiocon starts R&D Facility in Bio-XCell, MalaysiaDong-A to Establish Biosimilar Plant in Songdo © Industry Experts, All Rights ReservediBio Produces Rituximab in Plants -iv-
    • Nov 2012 GLOBAL BIOSIMILARS MARKET PRODUCTS, APPLICATIONS AND REGULATIONS TABLE 0F CONTENTSPharmerging Countries India and China Promising to Rollout Cheaper BiosimilarsBoehringer Ingelheim Ventures into BiosimilarsSanofi Announces Fresh Long-Term ObjectivesHospira Looks to Biosimilars and Increased use of Generics for GrowthStada, Richter to Collaborate on Biosimilar DevelopmentIMS Launches MIDAS BiosimilarsBiosmilars Luring Unlikely PartnershipsMerck, Hanwha Ink Enbrel DealLupin-NeuClone Deal to Develop Oncology BiosimilarsBrazil to Manufacture Biosimilar AdalimumabSpectrum, Viropro to Develop Rituximab BiosimilarSandoz Monitoring Ongoing Biosimilar G-CSF (filgrastim) StudySouth Korea to Promote Investments in BiosimilarsSandoz Announces Start of Phase II Trial for Biosimilar RituximabDr Reddy’s Releases Biosimilar Aranesp7. GLOBAL MARKET OVERVIEW7.1 Market Overview by Application Area7.1.1 Biosimilars Application Area Overview by Global Region7.1.1.1 Blood Disorders7.1.1.2 Chronic Diseases7.1.1.3 Growth Hormone Deficiency7.1.1.4 Oncology7.1.1.5 Other Biosimilar Applications7.2 Market Overview by Product Segment7.2.1 Biosimilars Product Segment Overview by Global Region7.2.1.1 Biosimilar Monoclonal Antibodies7.2.1.2 Biosimilar Erythropoietin7.2.1.3 Biosimilar Human Growth Hormone7.2.1.4 Biosimilar Insulin7.2.1.5 Biosimilar G-CSF7.2.1.6 Biosimilar Interferons7.2.1.7 Other Biosimilar ProductsPART B: REGIONAL MARKET PERSPECTIVEREGIONAL MARKET OVERVIEW1. THE UNITED STATES1.1 Market Overview by Application Area1.2 Market Overview by Product Segment1.3 Major Market PlayersAgilent Technologies, Inc.Amgen, Inc.Baxter International Inc.Biogen IDECDynavax Technologies CorporationHospira, Inc.iBio, Inc.Merck & Co., Inc.Momenta Pharmaceuticals inc © Industry Experts, All Rights Reserved -v-
    • Nov 2012 GLOBAL BIOSIMILARS MARKET PRODUCTS, APPLICATIONS AND REGULATIONS TABLE 0F CONTENTSMylan Inc.Perkinelmer, Inc.Pfizer IncWatson Pharmaceuticals, Inc.2. EUROPE2.1 Current Market Scenario2.2 Market Overview by Geographic Region2.3 Market Overview by Application Area2.3.1 Biosimilars Application Area Overview by European Region2.3.1.1 Blood Disorders2.3.1.2 Chronic Diseases2.3.1.3 Growth Hormone Deficiency2.3.1.4 Oncology2.3.1.5 Other Biosimilar Applications2.4 Market Overview by Product Segment2.4.1 Biosimilars Product Segment Overview by European Region2.4.1.1 Biosimilar Monoclonal Antibodies2.4.1.2 Biosimilar Erythropoietin2.4.1.3 Biosimilar Human Growth Hormone2.4.1.4 Biosimilar Insulin2.4.1.5 Biosimilar G-CSF2.4.1.6 Biosimilar Interferons2.4.1.7 Other Biosimilar Products2.5 Major Market PlayersActavis Group HF. (Iceland)Astrazeneca PLC (United Kingdom)BiogEnerix AG (Germany)Biopartners GmbH (Switzerland)Bioton S.A. (Poland)Boehringer Ingelheim GmbH (Germany)DSM Biologics (The Netherlands)GE Healthcare Ltd. (United Kingdom)Glaxosmithkline, PLC (United Kingdom)Hexal AG (Germany)Lonza Group Ltd (Switzerland)Medice Arzneimittel Pütter GmbH & Co Kg (Germany)Merck KGaA (Germany)Novartis AG (Switzerland)Roche Holding AG (Switzerland)Sandoz International GmbH (Germany)Sanofi (France)Stada Arzneimittel AG (Germany)2.6 European Market Overview by Country2.6.1 France2.6.1.1 Market Overview by Application Area2.6.1.2 Market Overview by Product Segment © Industry Experts, All Rights Reserved -vi-
    • Nov 2012 GLOBAL BIOSIMILARS MARKET PRODUCTS, APPLICATIONS AND REGULATIONS TABLE 0F CONTENTS2.6.2 Germany2.6.2.1 Market Overview by Application Area2.6.2.2 Market Overview by Product Segment2.6.3 Italy2.6.3.1 Market Overview by Application Area2.6.3.2 Market Overview by Product Segment2.6.4 Spain2.6.4.1 Market Overview by Application Area2.6.4.2 Market Overview by Product Segment2.6.5 United Kingdom2.6.5.1 Market Overview by Application Area2.6.5.2 Market Overview by Product Segment2.6.6 Rest of Europe2.6.6.1 Market Overview by Application Area2.6.6.2 Market Overview by Product Segment3. ASIA-PACIFIC3.1 Market Overview by Geographic Region3.2 Market Overview by Application Area3.2.1 Biosimilars Application Area Overview by Asia-Pacific Region3.2.1.1 Blood Disorders3.2.1.2 Chronic Diseases3.2.1.3 Growth Hormone Deficiency3.2.1.4 Oncology3.2.1.5 Other Biosimilar Applications3.3 Market Overview by Product Segment3.3.1 Biosimilars Product Segment Overview by Asia-Pacific Region3.3.1.1 Biosimilar Monoclonal Antibodies3.3.1.2 Biosimilar Erythropoietin3.3.1.3 Biosimilar Human Growth Hormone3.3.1.4 Biosimilar Insulin3.3.1.5 Biosimilar G-CSF3.3.1.6 Biosimilar Interferons3.3.1.7 Other Biosimilar Products3.4 Major Market Players3SBio Inc (China)Anhui Anke Biotechnology (Group) Co., Ltd. (China)Bharat Biotech International Limited (India)Biocon Ltd. (India)Cadila Healthcare Limited (India)Celltrion, Inc. (South Korea)Cipla Ltd. (India)Claris Lifesciences Limited (India)Daiichi Sankyo Company Limited (Japan)Dong-A Pharmaceutical Co., Ltd (South Korea)Dr. Reddys Laboratories Ltd. (India)Intas Biopharmaceuticals Ltd. (India)LG Life Sciences (South Korea) © Industry Experts, All Rights Reserved -vii-
    • Nov 2012 GLOBAL BIOSIMILARS MARKET PRODUCTS, APPLICATIONS AND REGULATIONS TABLE 0F CONTENTSMitsubishi Tanabe Pharma Corporation (Japan)Ranbaxy Laboratories Ltd. (India)Reliance Life Sciences Pvt Ltd (India)Samsung Biologics Co Ltd (South Korea)Shantha Biotechnics Ltd (India)Wockhardt Limited (India)3.5 Asia-Pacific Market Overview by Country3.5.1 China3.5.1.1 Current Market Scenario3.5.1.2 Market Overview by Application Area3.5.1.3 Market Overview by Product Segment3.5.2 India3.5.2.1 Current Market Scenario3.5.2.2 Market Overview by Application Area3.5.2.3 Market Overview by Product Segment3.5.3 South Korea3.5.3.1 Current Market Scenario3.5.3.2 Market Overview by Application Area3.5.3.3 Market Overview by Product Segment3.5.4 Rest of Asia-Pacific3.5.4.1 Market Overview by Application Area3.5.4.2 Market Overview by Product Segment4. REST OF WORLD4.1 Market Overview by Application Area4.2 Market Overview by Product Segment4.3 Major Market PlayersBioclones (Pty) Ltd. (South Africa)Cangene Corp. (Canada)Medicago Inc. (Canada)Teva Pharmaceutical Industries Ltd. (Israel)PART C: GUIDE TO THE INDUSTRY1. NORTH AMERICA1.1 Canada1.2 United States2. EUROPE2.1 France2.2 Germany2.3 Hungary2.4 Iceland2.5 Ireland2.6 Lithuania2.7 Malta2.8 Poland2.9 Russia2.10 Spain2.11 Switzerland © Industry Experts, All Rights Reserved -viii-
    • Nov 2012 GLOBAL BIOSIMILARS MARKET PRODUCTS, APPLICATIONS AND REGULATIONS TABLE 0F CONTENTS2.12 The Netherlands2.13 United Kingdom3. ASIA-PACIFIC3.1 Australia3.2 China3.3 India3.4 Japan3.5 Singapore3.6 South Korea3.7 Taiwan3.8 Vietnam4. REST OF WORLD4.1 Brazil4.2 Iran4.3 Israel4.4 Mexico4.5 South AfricaPART D: ANNEXURE1. RESEARCH METHODOLOGY2. THE QUESTIONNAIRE3. FEEDBACKCharts & GraphsPART A: GLOBAL MARKET PERSPECTIVEChart 1: The Leading mAbs and Years of Patent Expiry in United States and EuropeChart 2: The Biosimilar Manufacturers with Most No. of mAbs in PipelineChart 3: The Global Top-5 Biosimilar Manufacturers by Market Shares (%) for 2011 & 2012Chart 4: Analysis of Global Biosimilars Market (2012 & 2015) for Application in Blood Disorders by Geographic RegionChart 5: Analysis of Global Biosimilars Market (2012 & 2015) for Application in Chronic Diseases by Geographic RegionChart 6: Analysis of Global Biosimilars Market (2012 & 2015) for Application in Growth Hormone Deficiencies by GeographicRegionChart 7: Analysis of Global Biosimilars Market (2012 & 2015) for Application in Oncology by Geographic RegionChart 8: A Comparative Study on Biosimilars Between The Approaches of The European Union and The United StatesChart 9: The Innovator Products and their Corresponding Biosimilars by CompanyChart 10: Global Biosimilars Market Analysis (2009-2018) in USD MillionChart 11: Global Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, GrowthHormone Deficiency, Oncology and Other in USD MillionChart 12: Glance at 2009, 2013 and 2018 Global Biosimilars Market Share (%) by Application Area – Blood Disorders, ChronicDiseases, Growth Hormone Deficiency, Oncology and OtherChart 13: Glance at 2009, 2013 and 2018 Global Blood Disorders Market Share (%) of Biosimilars by Geographic Region –United States, Europe, Asia-Pacific and Rest of World in USD MillionChart 14: Glance at 2009, 2013 and 2018 Global Blood Disorders Market Share (%) of Biosimilars by Geographic Region –United States, Europe, Asia-Pacific and Rest of WorldChart 15: Global Biosimilars Market Analysis (2009-2018) for Application in Chronic Diseases by Geographic Region – UnitedStates, Europe, Asia-Pacific and Rest of World in USD MillionChart 16: Glance at 2009, 2013 and 2018 Global Chronic Diseases Market Share (%) of Biosimilars by Geographic Region –United States, Europe, Asia-Pacific and Rest of WorldChart 17: Global Biosimilars Market Analysis (2009-2018) for Application in Growth Hormone Deficiency by Geographic Region © Industry Experts, All Rights Reserved -ix-
    • Nov 2012 GLOBAL BIOSIMILARS MARKET PRODUCTS, APPLICATIONS AND REGULATIONS TABLE 0F CONTENTS– United States, Europe, Asia-Pacific and Rest of World in USD MillionChart 18: Glance at 2009, 2013 and 2018 Global Growth Hormone Deficiency Market Share (%) of Biosimilars by GeographicRegion – United States, Europe, Asia-Pacific and Rest of WorldChart 19: Global Biosimilars Market Analysis (2009-2018) for Application in Oncology by Geographic Region – United States,Europe, Asia-Pacific and Rest of World in USD MillionChart 20: Glance at 2009, 2013 and 2018 Global Oncology Market Share (%) of Biosimilars by Geographic Region – UnitedStates, Europe, Asia-Pacific and Rest of WorldChart 21: Global Biosimilars Market Analysis (2009-2018) for Other Applications by Geographic Region – United States,Europe, Asia-Pacific and Rest of World in USD MillionChart 22: Glance at 2009, 2013 and 2018 Global Other Biosimilar Applications Market Share (%) of Biosimilars by GeographicRegion – United States, Europe, Asia-Pacific and Rest of WorldChart 23: Global Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin, HumanGrowth Hormone, Insulin, G-CSF, Interferons and Other in USD MillionChart 24: Glance at 2009, 2013 and 2018 Global Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies,Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and OtherChart 25: Global Biosimilar Monoclonal Antibodies Market Analysis (2009-2018) by Geographic Region – United States,Europe, Asia-Pacific and Rest of World in USD MillionChart 26: Glance at 2009, 2013 and 2018 Global Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region –United States, Europe, Asia-Pacific and Rest of WorldChart 27: Global Biosimilar Erythropoietin Market Analysis (2009-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD MillionChart 28: Glance at 2009, 2013 and 2018 Global Biosimilar Erythropoietin Market Share (%) by Geographic Region – UnitedStates, Europe, Asia-Pacific and Rest of WorldChart 29: Global Biosimilar Human Growth Hormone Market Analysis (2009-2018) by Geographic Region – United States,Europe, Asia-Pacific and Rest of World in USD MillionChart 30: Glance at 2009, 2013 and 2018 Global Biosimilar Human Growth Hormone Market Share (%) by Geographic Region– United States, Europe, Asia-Pacific and Rest of WorldChart 31: Global Biosimilar Insulin Market Analysis (2009-2018) by Geographic Region – United States, Europe, Asia-Pacificand Rest of World in USD MillionChart 32: Glance at 2009, 2013 and 2018 Global Biosimilar Insulin Market Share (%) by Geographic Region – United States,Europe, Asia-Pacific and Rest of WorldChart 33: Global Biosimilar G-CSF Market Analysis (2009-2018) by Geographic Region – United States, Europe, Asia-Pacificand Rest of World in USD MillionChart 34: Glance at 2009, 2013 and 2018 Global Biosimilar G-CSF Market Share (%) by Geographic Region – United States,Europe, Asia-Pacific and Rest of WorldChart 35: Global Biosimilar Interferons Market Analysis (2009-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD MillionChart 36: Glance at 2009, 2013 and 2018 Global Biosimilar Interferons Market Share (%) by Geographic Region – UnitedStates, Europe, Asia-Pacific and Rest of WorldChart 37: Global Other Biosimilar Products Market Analysis (2009-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD MillionChart 38: Glance at 2009, 2013 and 2018 Global Other Biosimilar Products Market Share (%) by Geographic Region – UnitedStates, Europe, Asia-Pacific and Rest of WorldPART B: REGIONAL MARKET PERSPECTIVEChart 39: The Projection of Largest Regions in terms of Market Growth (2009-2018) for Biosimilars by Geography – UnitedStates, Europe and Asia-PacificChart 40: Global Biosimilars Market Analysis (2009-2018) by Geographic Region – United States, Europe, Asia-Pacific and Restof World in USD Million © Industry Experts, All Rights Reserved -x-
    • Nov 2012 GLOBAL BIOSIMILARS MARKET PRODUCTS, APPLICATIONS AND REGULATIONS TABLE 0F CONTENTSChart 41: Glance at 2009, 2013 and 2018 Global Biosimilars Market Share (%) by Geographic Region – United States, Europe,Asia-Pacific and Rest of WorldTHE UNITED STATESChart 42: United States Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases,Growth Hormone Deficiency, Oncology and Other in USD MillionChart 43: Glance at 2009, 2013 and 2018 United States Biosimilars Market Share (%) by Application Area – Blood Disorders,Chronic Diseases, Growth Hormone Deficiency, Oncology and OtherChart 44: United States Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin,Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD MillionChart 45: Glance at 2009, 2013 and 2018 United States Biosimilars Market Share (%) by Product Segment – MonoclonalAntibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and OtherEUROPEChart 46: European Biosimilars Market Analysis (2009-2018) by Geographic Region – France, Germany, Italy, Spain, UnitedKingdom and Rest of Europe in USD MillionChart 47: Glance at 2009, 2013 and 2018 European Biosimilars Market Share (%) by Geographic Region – France, Germany,Italy, Spain, United Kingdom and Rest of EuropeChart 48: European Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, GrowthHormone Deficiency, Oncology and Other in USD MillionChart 49: Glance at 2009, 2013 and 2018 European Biosimilars Market Share (%) by Application Area – Blood Disorders,Chronic Diseases, Growth Hormone Deficiency, Oncology and OtherChart 50: European Biosimilars Market Analysis (2009-2018) for Application in Blood Disorders by Geographic Region –France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD MillionChart 51: Glance at 2009, 2013 and 2018 European Blood Disorders Market Share (%) of Biosimilars by Geographic Region –France, Germany, Italy, Spain, United Kingdom and Rest of EuropeChart 52: European Biosimilars Market Analysis (2009-2018) for Application in Chronic Diseases by Geographic Region –France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD MillionChart 53: Glance at 2009, 2013 and 2018 European Chronic Diseases Market Share (%) of Biosimilars by Geographic Region –France, Germany, Italy, Spain, United Kingdom and Rest of EuropeChart 54: European Biosimilars Market Analysis (2009-2018) for Application in Growth Hormone Deficiency by GeographicRegion – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD MillionChart 55: Glance at 2009, 2013 and 2018 European Growth Hormone Deficiency Market Share (%) of Biosimilars byGeographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of EuropeChart 56: European Biosimilars Market Analysis (2009-2018) for Application in Oncology by Geographic Region – France,Germany, Italy, Spain, United Kingdom and Rest of Europe in USD MillionChart 57: Glance at 2009, 2013 and 2018 European Oncology Market Share (%) of Biosimilars by Geographic Region – France,Germany, Italy, Spain, United Kingdom and Rest of EuropeChart 58: European Biosimilars Market Analysis (2009-2018) for Other Applications by Geographic Region – France, Germany,Italy, Spain, United Kingdom and Rest of Europe in USD MillionChart 59: Glance at 2009, 2013 and 2018 European Other Biosimilar Applications Market Share (%) of Biosimilars byGeographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of EuropeChart 60: European Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin,Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD MillionChart 61: Glance at 2009, 2013 and 2018 European Biosimilars Market Share (%) by Product Segment – MonoclonalAntibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and OtherChart 62: European Biosimilar Monoclonal Antibodies Market Analysis (2009-2018) by Geographic Region – France, Germany,Italy, Spain, United Kingdom and Rest of Europe in USD MillionChart 63: Glance at 2009, 2013 and 2018 European Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region– France, Germany, Italy, Spain, United Kingdom and Rest of Europe © Industry Experts, All Rights Reserved -xi-
    • Nov 2012 GLOBAL BIOSIMILARS MARKET PRODUCTS, APPLICATIONS AND REGULATIONS TABLE 0F CONTENTSChart 64: European Biosimilar Erythropoietin Market Analysis (2009-2018) by Geographic Region – France, Germany, Italy,Spain, United Kingdom and Rest of Europe in USD MillionChart 65: Glance at 2009, 2013 and 2018 European Biosimilar Erythropoietin Market Share (%) by Geographic Region –France, Germany, Italy, Spain, United Kingdom and Rest of EuropeChart 66: European Biosimilar Human Growth Hormone Market Analysis (2009-2018) by Geographic Region – France,Germany, Italy, Spain, United Kingdom and Rest of Europe in USD MillionChart 67: Glance at 2009, 2013 and 2018 European Biosimilar Human Growth Hormone Market Share (%) by GeographicRegion – France, Germany, Italy, Spain, United Kingdom and Rest of EuropeChart 68: European Biosimilar Insulin Market Analysis (2009-2018) by Geographic Region – France, Germany, Italy, Spain,United Kingdom and Rest of Europe in USD MillionChart 69: Glance at 2009, 2013 and 2018 European Biosimilar Insulin Market Share (%) by Geographic Region – France,Germany, Italy, Spain, United Kingdom and Rest of EuropeChart 70: European Biosimilar G-CSF Market Analysis (2009-2018) by Geographic Region – France, Germany, Italy, Spain,United Kingdom and Rest of Europe in USD MillionChart 71: Glance at 2009, 2013 and 2018 European Biosimilar G-CSF Market Share (%) by Geographic Region – France,Germany, Italy, Spain, United Kingdom and Rest of EuropeChart 72: European Biosimilar Interferons Market Analysis (2009-2018) by Geographic Region – France, Germany, Italy, Spain,United Kingdom and Rest of Europe in USD MillionChart 73: Glance at 2009, 2013 and 2018 European Biosimilar Interferons Market Share (%) by Geographic Region – France,Germany, Italy, Spain, United Kingdom and Rest of EuropeChart 74: European Other Biosimilar Products Market Analysis (2009-2018) by Geographic Region – France, Germany, Italy,Spain, United Kingdom and Rest of Europe in USD MillionChart 75: Glance at 2009, 2013 and 2018 European Other Biosimilar Products Market Share (%) by Geographic Region –France, Germany, Italy, Spain, United Kingdom and Rest of EuropeFranceChart 76: French Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, GrowthHormone Deficiency, Oncology and Other in USD MillionChart 77: Glance at 2009, 2013 and 2018 French Biosimilars Market Share (%) by Application Area – Blood Disorders, ChronicDiseases, Growth Hormone Deficiency, Oncology and OtherChart 78: French Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin,Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD MillionChart 79: Glance at 2009, 2013 and 2018 French Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies,Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and OtherGermanyChart 80: German Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, GrowthHormone Deficiency, Oncology and Other in USD MillionChart 81: Glance at 2009, 2013 and 2018 German Biosimilars Market Share (%) by Application Area – Blood Disorders, ChronicDiseases, Growth Hormone Deficiency, Oncology and OtherChart 82: German Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin,Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD MillionChart 83: Glance at 2009, 2013 and 2018 German Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies,Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and OtherItalyChart 84: Italian Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, GrowthHormone Deficiency, Oncology and Other in USD MillionChart 85: Glance at 2009, 2013 and 2018 Italian Biosimilars Market Share (%) by Application Area – Blood Disorders, ChronicDiseases, Growth Hormone Deficiency, Oncology and OtherChart 86: Italian Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human © Industry Experts, All Rights Reserved -xii-
    • Nov 2012 GLOBAL BIOSIMILARS MARKET PRODUCTS, APPLICATIONS AND REGULATIONS TABLE 0F CONTENTSGrowth Hormone, Insulin, G-CSF, Interferons and Other in USD MillionChart 87: Glance at 2009, 2013 and 2018 Italian Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies,Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and OtherSpainChart 88: Spanish Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, GrowthHormone Deficiency, Oncology and Other in USD MillionChart 89: Glance at 2009, 2013 and 2018 Spanish Biosimilars Market Share (%) by Application Area – Blood Disorders, ChronicDiseases, Growth Hormone Deficiency, Oncology and OtherChart 90: Spanish Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin,Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD MillionChart 91: Glance at 2009, 2013 and 2018 Spanish Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies,Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and OtherUnited KingdomChart 92: United Kingdom Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases,Growth Hormone Deficiency, Oncology and Other in USD MillionChart 93: Glance at 2009, 2013 and 2018 United Kingdom Biosimilars Market Share (%) by Application Area – Blood Disorders,Chronic Diseases, Growth Hormone Deficiency, Oncology and OtherChart 94: United Kingdom Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies,Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD MillionChart 95: Glance at 2009, 2013 and 2018 United Kingdom Biosimilars Market Share (%) by Product Segment – MonoclonalAntibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and OtherRest of EuropeChart 96: Rest of Europe Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases,Growth Hormone Deficiency, Oncology and Other in USD MillionChart 97: Glance at 2009, 2013 and 2018 Rest of Europe Biosimilars Market Share (%) by Application Area – Blood Disorders,Chronic Diseases, Growth Hormone Deficiency, Oncology and OtherChart 98: Rest of Europe Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies,Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD MillionChart 99: Glance at 2009, 2013 and 2018 Rest of Europe Biosimilars Market Share (%) by Product Segment – MonoclonalAntibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and OtherASIA-PACIFICChart 100: Asia-Pacific Biosimilars Market Analysis (2009-2018) by Geographic Region – China, India, South Korea and Rest ofAsia-Pacific in USD MillionChart 101: Glance at 2009, 2013 and 2018 Asia-Pacific Biosimilars Market Share (%) by Geographic Region – China, India,South Korea and Rest of Asia-PacificChart 102: Asia-Pacific Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases,Growth Hormone Deficiency, Oncology and Other in USD MillionChart 103: Glance at 2009, 2013 and 2018 Asia-Pacific Biosimilars Market Share (%) by Application Area – Blood Disorders,Chronic Diseases, Growth Hormone Deficiency, Oncology and OtherChart 104: Asia-Pacific Biosimilars Market Analysis (2009-2018) for Application in Blood Disorders by Geographic Region –China, India, South Korea and Rest of Asia-Pacific in USD MillionChart 105: Glance at 2009, 2013 and 2018 Asia-Pacific Blood Disorders Market Share (%) of Biosimilars by Geographic Region– China, India, South Korea and Rest of Asia-PacificChart 106: Asia-Pacific Biosimilars Market Analysis (2009-2018) for Application in Chronic Diseases by Geographic Region –China, India, South Korea and Rest of Asia-Pacific in USD MillionChart 107: Glance at 2009, 2013 and 2018 Asia-Pacific Chronic Diseases Market Share (%) of Biosimilars by GeographicRegion – China, India, South Korea and Rest of Asia-Pacific © Industry Experts, All Rights Reserved -xiii-
    • Nov 2012 GLOBAL BIOSIMILARS MARKET PRODUCTS, APPLICATIONS AND REGULATIONS TABLE 0F CONTENTSChart 108: Asia-Pacific Biosimilars Market Analysis (2009-2018) for Application in Growth Hormone Deficiency by GeographicRegion – China, India, South Korea and Rest of Asia-Pacific in USD MillionChart 109: Glance at 2009, 2013 and 2018 Asia-Pacific Growth Hormone Deficiency Market Share (%) of Biosimilars byGeographic Region – China, India, South Korea and Rest of Asia-PacificChart 110: Asia-Pacific Biosimilars Market Analysis (2009-2018) for Application in Oncology by Geographic Region – China,India, South Korea and Rest of Asia-Pacific in USD MillionChart 111: Glance at 2009, 2013 and 2018 Asia-Pacific Oncology Market Share (%) of Biosimilars by Geographic Region –China, India, South Korea and Rest of Asia-PacificChart 112: Asia-Pacific Biosimilars Market Analysis (2009-2018) for Other Applications by Geographic Region – China, India,South Korea and Rest of Asia-Pacific in USD MillionChart 113: Glance at 2009, 2013 and 2018 Asia-Pacific Other Biosimilar Applications Market Share (%) of Biosimilars byGeographic Region – China, India, South Korea and Rest of Asia-PacificChart 114: Asia-Pacific Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin,Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD MillionChart 115: Glance at 2009, 2013 and 2018 Asia-Pacific Biosimilars Market Share (%) by Product Segment – MonoclonalAntibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and OtherChart 116: Asia-Pacific Biosimilar Monoclonal Antibodies Market Analysis (2009-2018) by Geographic Region – China, India,South Korea and Rest of Asia-Pacific in USD MillionChart 117: Glance at 2009, 2013 and 2018 Asia-Pacific Biosimilar Monoclonal Antibodies Market Share (%) by GeographicRegion – China, India, South Korea and Rest of Asia-PacificChart 118: Asia-Pacific Biosimilar Erythropoietin Market Analysis (2009-2018) by Geographic Region – China, India, SouthKorea and Rest of Asia-Pacific in USD MillionChart 119: Glance at 2009, 2013 and 2018 Asia-Pacific Biosimilar Erythropoietin Market Share (%) by Geographic Region –China, India, South Korea and Rest of Asia-PacificChart 120: Asia-Pacific Biosimilar Human Growth Hormone Market Analysis (2009-2018) by Geographic Region – China, India,South Korea and Rest of Asia-Pacific in USD MillionChart 121: Glance at 2009, 2013 and 2018 Asia-Pacific Biosimilar Human Growth Hormone Market Share (%) by GeographicRegion – China, India, South Korea and Rest of Asia-PacificChart 122: Asia-Pacific Biosimilar Insulin Market Analysis (2009-2018) by Geographic Region – China, India, South Korea andRest of Asia-Pacific in USD MillionChart 123: Glance at 2009, 2013 and 2018 Asia-Pacific Biosimilar Insulin Market Share (%) by Geographic Region – China,India, South Korea and Rest of Asia-PacificChart 124: Asia-Pacific Biosimilar G-CSF Market Analysis (2009-2018) by Geographic Region – China, India, South Korea andRest of Asia-Pacific in USD MillionChart 125: Glance at 2009, 2013 and 2018 Asia-Pacific Biosimilar G-CSF Market Share (%) by Geographic Region – China,India, South Korea and Rest of Asia-PacificChart 126: Asia-Pacific Biosimilar Interferons Market Analysis (2009-2018) by Geographic Region – China, India, South Koreaand Rest of Asia-Pacific in USD MillionChart 127: Glance at 2009, 2013 and 2018 Asia-Pacific Biosimilar Interferons Market Share (%) by Geographic Region – China,India, South Korea and Rest of Asia-PacificChart 128: Asia-Pacific Other Biosimilar Products Market Analysis (2009-2018) by Geographic Region – China, India, SouthKorea and Rest of Asia-Pacific in USD MillionChart 129: Glance at 2009, 2013 and 2018 Asia-Pacific Other Biosimilar Products Market Share (%) by Geographic Region –China, India, South Korea and Rest of Asia-PacificChinaChart 130: Chinese Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, GrowthHormone Deficiency, Oncology and Other in USD MillionChart 131: Glance at 2009, 2013 and 2018 Chinese Biosimilars Market Share (%) by Application Area – Blood Disorders, © Industry Experts, All Rights Reserved -xiv-
    • Nov 2012 GLOBAL BIOSIMILARS MARKET PRODUCTS, APPLICATIONS AND REGULATIONS TABLE 0F CONTENTSChronic Diseases, Growth Hormone Deficiency, Oncology and OtherChart 132: Chinese Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin,Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD MillionChart 133: Glance at 2009, 2013 and 2018 Chinese Biosimilars Market Share (%) by Product Segment – MonoclonalAntibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and OtherIndiaChart 134: Indian Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, GrowthHormone Deficiency, Oncology and Other in USD MillionChart 135: Glance at 2009, 2013 and 2018 Indian Biosimilars Market Share (%) by Application Area – Blood Disorders, ChronicDiseases, Growth Hormone Deficiency, Oncology and OtherChart 136: Indian Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin,Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD MillionChart 137: Glance at 2009, 2013 and 2018 Indian Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies,Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and OtherSouth KoreaChart 138: Korean Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, GrowthHormone Deficiency, Oncology and Other in USD MillionChart 139: Glance at 2009, 2013 and 2018 Korean Biosimilars Market Share (%) by Application Area – Blood Disorders,Chronic Diseases, Growth Hormone Deficiency, Oncology and OtherChart 140: Korean Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin,Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD MillionChart 141: Glance at 2009, 2013 and 2018 Korean Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies,Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and OtherRest of Asia-PacificChart 142: Rest of Asia-Pacific Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, ChronicDiseases, Growth Hormone Deficiency, Oncology and Other in USD MillionChart 143: Glance at 2009, 2013 and 2018 Rest of Asia-Pacific Biosimilars Market Share (%) by Application Area – BloodDisorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and OtherChart 144: Rest of Asia-Pacific Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies,Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD MillionChart 145: Glance at 2009, 2013 and 2018 Rest of Asia-Pacific Biosimilars Market Share (%) by Product Segment –Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and OtherREST OF WORLDChart 146: Rest of World Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases,Growth Hormone Deficiency, Oncology and Other in USD MillionChart 147: Glance at 2009, 2013 and 2018 Rest of World Biosimilars Market Share (%) by Application Area – Blood Disorders,Chronic Diseases, Growth Hormone Deficiency, Oncology and OtherChart 148: Rest of World Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies,Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD MillionChart 149: Glance at 2009, 2013 and 2018 Rest of World Biosimilars Market Share (%) by Product Segment – MonoclonalAntibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and OtherMAJOR GLOBAL MARKET PLAYERS:3SBio IncActavis Group HF.Agilent Technologies, Inc. © Industry Experts, All Rights Reserved -xv-
    • Nov 2012 GLOBAL BIOSIMILARS MARKET PRODUCTS, APPLICATIONS AND REGULATIONS TABLE 0F CONTENTSAmgen, Inc.Astrazeneca PlcBaxter International Inc.Biocon Ltd.Biogen IDECBioton S.A.Boehringer Ingelheim GmbHCadila Healthcare LimitedCangene Corp.Celltrion, Inc.Cipla Ltd.Daiichi Sankyo Company LimitedDong-A Pharmaceutical Co., LtdDr. Reddys Laboratories Ltd.DSM BiologicsGE Healthcare Ltd.Glaxosmithkline, PlcHospira, Inc.iBio, Inc.LG Life SciencesLonza Group LtdMedice Arzneimittel Pütter GmbH & Co KGMerck & Co., Inc.Merck KGaAMitsubishi Tanabe Pharma CorporationMylan Inc.Novartis AGPerkinelmer, Inc.Pfizer IncRanbaxy Laboratories Ltd.Reliance Life Sciences Pvt LtdRoche Holding AGSamsung Biologics Co LtdSandoz International GmbHSanofiShantha Biotechnics LtdStada Arzneimittel AGTeva Pharmaceutical Industries Ltd.Watson Pharmaceuticals, Inc.Wockhardt LimitedFor more information please visit: Global Biosimilars Market - Products, Applicationsand Regulations © Industry Experts, All Rights Reserved -xvi-